Publications by Øyvind Sverre Bruland

215 publications found

Publications 2024

1. Hompland I, Boye K, Wiedswang AM, Papakonstantinou A, Røsok B, Joensuu H, Bruland Ø (2024)
   Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study
   Acta Oncol, 63, 288-293
   DOI 10.2340/1651-226X.2024.39851, PubMed 38712513
2. Machak GN, Bruland ØS, Romanova TN, Kovalev AV (2024)
   Denosumab induction and Zoledronic acid maintenance therapy for recurrent unresectable giant cell tumour of the distal tibia: A case report with sustained tumour control after drug withdrawal
   J Bone Oncol, 45, 100596
   DOI 10.1016/j.jbo.2024.100596, PubMed 38545297

Publications 2023

1. Bruland ØS, Larsen RH, Baum RP, Juzeniene A (2023)
   Editorial: Targeted alpha particle therapy in oncology
   Front Med (Lausanne), 10, 1165747
   DOI 10.3389/fmed.2023.1165747, PubMed 36960341
2. Fauske L, Jebsen NL, Bondevik H, Bruland ØS (2023)
   Exploring the Patient Perspective of Bone Sarcoma Survivors Who Have Undergone Particle Radiotherapy Abroad
   Anticancer Res, 43 (5), 2031-2039
   DOI 10.21873/anticanres.16364, PubMed 37097689
3. Grønningsæter SR, Blakkisrud J, Selboe S, Revheim ME, Bruland ØS, Bønsdorff TB, Larsen SG, Stokke C (2023)
   Radiation safety considerations for the use of radium-224-calciumcarbonate-microparticles in patients with peritoneal metastasis
   Front Med (Lausanne), 10, 1058914
   DOI 10.3389/fmed.2023.1058914, PubMed 36844217
4. Juzeniene A, Stenberg VY, Bruland ØS, Revheim ME, Larsen RH (2023)
   Dual targeting with ²²⁴Ra/²¹²Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach
   Front Med (Lausanne), 9, 1051825
   DOI 10.3389/fmed.2022.1051825, PubMed 36733936
5. Larsen SG, Graf W, Mariathasan AB, Sørensen O, Spasojevic M, Goscinski MA, Selboe S, Lundstrøm N, Holtermann A, Revheim ME, Bruland ØS (2023)
   First experience with ²²⁴Radium-labeled microparticles (Radspherin®) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study)
   Front Med (Lausanne), 10, 1070362
   DOI 10.3389/fmed.2023.1070362, PubMed 36936230
6. Mensali N, Köksal H, Joaquina S, Wernhoff P, Casey NP, Romecin P, Panisello C, Rodriguez R, Vimeux L, Juzeniene A, Myhre MR, Fåne A, Ramírez CC, Maggadottir SM, Duru AD, Georgoudaki AM, Grad I, Maturana AD, Gaudernack G, Kvalheim G, Carcaboso AM, de Alava E, Donnadieu E, Bruland ØS, Menendez P et al. (2023)
   ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma
   Nat Commun, 14 (1), 3375
   DOI 10.1038/s41467-023-39097-x, PubMed 37291203
7. Palmerini E, Reichardt P, Hall KS, Bertulli R, Bielack SS, Comandone A, Egerer G, Hansmeier A, Kevric M, Carretta E, Hansson L, Jebsen N, Eriksson M, Bruland ØS, Donati DM, Ibrahim T, Smeland S, Ferrari S (2023)
   Outcome of rare primary malignant bone sarcoma treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.)
   Cancer, 129 (22), 3564-3573
   DOI 10.1002/cncr.34964, PubMed 37530385
8. Thorgersen EB, Asvall J, Schjalm C, McAdam KE, Bruland ØS, Larsen SG, Mollnes TE (2023)
   Effect of Intraperitoneal ²²⁴Radium-Labelled Microparticles on Compartmentalized Inflammation After Cytoreductive Surgery and Hypertherm Intraperitoneal Chemotherapy
   Technol Cancer Res Treat, 22, 15330338231192902
   DOI 10.1177/15330338231192902, PubMed 37574949
9. van de Wal D, Fauske L, Bruland ØS, Jones RL, Kasper B, Wilson R, van der Graaf WTA, Husson O (2023)
   Psychological and social challenges of patients with locally advanced and metastatic gastrointestinal stromal tumours (GIST) on long-term treatment with tyrosine kinase inhibitors: a qualitative study with patients and medical oncologists
   Support Care Cancer, 31 (6), 352
   DOI 10.1007/s00520-023-07810-7, PubMed 37233829

Publications 2022

1. Barnes DJ, Dutton P, Bruland Ø, Gelderblom H, Faleti A, Bühnemann C, van Maldegem A, Johnson H, Poulton L, Love S, Tiemeier G, van Beelen E, Herbschleb K, Haddon C, Billingham L, Bradley K, Ferrari S, Palmerini E, Picci P, Dirksen U, Strauss SJ, Hogendoorn PCW, Buddingh E, Blay JY, Cleton-Jansen AM et al. (2022)
   Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)
   BMC Cancer, 22 (1), 629
   DOI 10.1186/s12885-022-09697-9, PubMed 35672690
2. Boye K, Lobmaier I, Kobbeltvedt MR, Thorkildsen J, Taksdal I, Bjerkehagen B, Bruland ØS, Zaikova O, Sundby Hall K, Hompland I (2022)
   Real-world evidence on perioperative chemotherapy in localized soft tissue sarcoma of the extremities and trunk wall; a population-based study
   Acta Oncol, 61 (7), 793-800
   DOI 10.1080/0284186X.2022.2082259, PubMed 35698755
3. Fauske L, Wærstad PH, Hompland I, Bruland ØS (2022)
   Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal Tumours
   Anticancer Res, 42 (2), 955-963
   DOI 10.21873/anticanres.15555, PubMed 35093895
4. Schmid MP, Harrabi S, Herfarth K, Bruland ØS, Welzel T, Haberer T, Ellerbrock M, Debus J, Uhl M, Seidensaal K (2022)
   Particle Therapy in Adult Patients with Pelvic Ewing Sarcoma-Tumor and Treatment Characteristics and Early Clinical Outcomes
   Cancers (Basel), 14 (24)
   DOI 10.3390/cancers14246045, PubMed 36551530
5. Stenberg VY, Tornes AJK, Nilsen HR, Revheim ME, Bruland ØS, Larsen RH, Juzeniene A (2022)
   Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand ²¹²Pb-NG001
   Cancers (Basel), 14 (11)
   DOI 10.3390/cancers14112784, PubMed 35681766
6. Tornes AJK, Stenberg VY, Larsen RH, Bruland ØS, Revheim ME, Juzeniene A (2022)
   Targeted alpha therapy with the ²²⁴Ra/²¹²Pb-TCMC-TP-3 dual alpha solution in a multicellular tumor spheroid model of osteosarcoma
   Front Med (Lausanne), 9, 1058863
   DOI 10.3389/fmed.2022.1058863, PubMed 36507500

Publications 2021

1. Fauske L, Bruland ØS, Dahl AA, Myklebostad A, Reme SE (2021)
   Does the Lightning Process Training Programme Reduce Chronic Fatigue in Adolescent and Young Adult Cancer Survivors? A Mixed-Methods Pilot Study
   Cancers (Basel), 13 (16)
   DOI 10.3390/cancers13164076, PubMed 34439229
2. Juzeniene A, Stenberg VY, Bruland ØS, Larsen RH (2021)
   Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
   Cancers (Basel), 13 (4)
   DOI 10.3390/cancers13040779, PubMed 33668474
3. Kerboeuf M, Koppang EO, Haaland AH, Lingaas F, Bruland ØS, Teige J, Moe L (2021)
   Early immunohistochemical detection of pulmonary micrometastases in dogs with osteosarcoma
   Acta Vet Scand, 63 (1), 41
   DOI 10.1186/s13028-021-00608-9, PubMed 34732227
4. Lansu J, Bovée JVMG, Braam P, van Boven H, Flucke U, Bonenkamp JJ, Miah AB, Zaidi SH, Thway K, Bruland ØS, Baldini EH, Jebsen NL, Scholten AN, van den Ende PLA, Krol ADG, Ubbels JF, van der Hage JA, van Werkhoven E, Klomp HM, van der Graaf WTA, van Coevorden F, Schrage Y, van Houdt WJ, Haas RL (2021)
   Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial
   JAMA Oncol, 7 (1), e205865
   DOI 10.1001/jamaoncol.2020.5865, PubMed 33180100
5. Li RG, Napoli E, Jorstad IS, Bønsdorff TB, Juzeniene A, Bruland ØS, Larsen RH, Westrøm S (2021)
   Calcium Carbonate Microparticles as Carriers of ²²⁴Ra: Impact of Specific Activity in Mice with Intraperitoneal Ovarian Cancer
   Curr Radiopharm, 14 (2), 145-153
   DOI 10.2174/1874471013666201201102056, PubMed 33261548
6. Napoli E, Bønsdorff TB, Jorstad IS, Bruland ØS, Larsen RH, Westrøm S (2021)
   Radon-220 diffusion from 224Ra-labeled calcium carbonate microparticles: Some implications for radiotherapeutic use
   PLoS One, 16 (3), e0248133
   DOI 10.1371/journal.pone.0248133, PubMed 33662039
7. Revheim ME, Hole KH, Mo T, Bruland ØS, Reitan E, Julsrud L, Seierstad T (2021)
   Multimodal functional imaging for early response assessment in patients with gastrointestinal stromal tumor treated with tyrosine kinase inhibitors
   Acta Radiol, 63 (8), 995-1004
   DOI 10.1177/02841851211027389, PubMed 34171968
8. Spasojevic M, Mariathasan AB, Frich L, Bruland ØS, Larsen SG, Stoldt S (2021)
   [Cancer therapy with isolated limb perfusion]
   Tidsskr Nor Laegeforen, 141 (2021-12)
   DOI 10.4045/tidsskr.21.0194, PubMed 34505491
9. Stenberg VY, Larsen RH, Ma LW, Peng Q, Juzenas P, Bruland ØS, Juzeniene A (2021)
   Evaluation of the PSMA-Binding Ligand ²¹²Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer
   Int J Mol Sci, 22 (9)
   DOI 10.3390/ijms22094815, PubMed 34062920
10. van Eck I, den Hollander D, Lidington E, Hentschel L, Eichler M, Salah S, Singer S, Pinto M, Fauske L, Fiore M, Nixon I, Constantinidou A, Desar IME, Bonenkamp JJ, van Houdt WJ, Reuvers MJP, Haas RLM, Bruland ØS, Kasper B, van der Graaf WTA, Husson O (2021)
    Health-Related Quality of Life Issues Experienced by Thoracic and Breast Sarcoma Patients: A Rare and Understudied Group
    J Clin Med, 10 (22)
    DOI 10.3390/jcm10225334, PubMed 34830615

Publications 2020

1. Hall KS, Bruland ØS, Bjerkehagen B, Lidbrink E, Jebsen N, Hagberg H, Papworth K, Hagberg O, Trovik C, Bauer H, Eriksson M (2020)
   Preoperative accelerated radiotherapy combined with chemotherapy in a defined cohort of patients with high risk soft tissue sarcoma: a Scandinavian Sarcoma Group study
   Clin Sarcoma Res, 10 (1), 22
   DOI 10.1186/s13569-020-00145-5, PubMed 33292545
2. Hompland I, Fauske L, Lorem GF, Bruland ØS (2020)
   Use of a simple form to facilitate communication on long-term consequences of treatment in sarcoma survivors
   Clin Sarcoma Res, 10, 2
   DOI 10.1186/s13569-019-0124-3, PubMed 31969978
3. König M, Osnes T, Bruland Ø, Sundby Hall K, Bratland Å, Meling TR (2020)
   The Role of Adjuvant Treatment in Craniofacial Malignancy: A Critical Review
   Front Oncol, 10, 1402
   DOI 10.3389/fonc.2020.01402, PubMed 32850452
4. Napoli E, Stenberg VY, Juzeniene A, Hjellum GE, Bruland ØS, Larsen RH (2020)
   Calibration of sodium iodide detectors and reentrant ionization chambers for ²¹²Pb activity in different geometries by HPGe activity determined samples
   Appl Radiat Isot, 166, 109362
   DOI 10.1016/j.apradiso.2020.109362, PubMed 32979756
5. Stenberg VY, Juzeniene A, Bruland ØS, Larsen RH (2020)
   In situ Generated ²¹²Pb-PSMA Ligand in a ²²⁴Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells
   Curr Radiopharm, 13 (2), 130-141
   DOI 10.2174/1874471013666200511000532, PubMed 32389119
6. Stenberg VY, Juzeniene A, Chen Q, Yang X, Bruland ØS, Larsen RH (2020)
   Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [²¹² Pb]Pb-NG001 for prostate cancer
   J Labelled Comp Radiopharm, 63 (3), 129-143
   DOI 10.1002/jlcr.3825, PubMed 31919866

Publications 2019

1. Berner K, Bruland ØS (2019)
   Prognostic Impact of Proximal Versus Distal Localization in Extremity Long Bone Osteosarcomas
   Anticancer Res, 39 (5), 2459-2466
   DOI 10.21873/anticanres.13365, PubMed 31092440
2. Fauske L, Hompland I, Lorem G, Bondevik H, Bruland ØS (2019)
   Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study
   Clin Sarcoma Res, 9, 6
   DOI 10.1186/s13569-019-0116-3, PubMed 31061697
3. Jha AK, Neupane P, Pradhan M, Sharma KS, Shrestha S, Sigdel PR, Smeland S, Bruland ØS (2019)
   Ewing Sarcoma in Nepal Treated With Combined Chemotherapy and Definitive Radiotherapy
   J Glob Oncol, 5, 1-10
   DOI 10.1200/JGO.19.00015, PubMed 30917070
4. Köksal H, Müller E, Inderberg EM, Bruland Ø, Wälchli S (2019)
   Treating osteosarcoma with CAR T cells
   Scand J Immunol, 89 (3), e12741
   DOI 10.1111/sji.12741, PubMed 30549299
5. Thorkildsen J, Taksdal I, Bjerkehagen B, Haugland HK, Børge Johannesen T, Viset T, Norum OJ, Bruland Ø, Zaikova O (2019)
   Chondrosarcoma in Norway 1990-2013; an epidemiological and prognostic observational study of a complete national cohort
   Acta Oncol, 58 (3), 273-282
   DOI 10.1080/0284186X.2018.1554260, PubMed 30632866

Publications 2018

1. Berner K, Johannesen TB, Hall KS, Bruland ØS (2018)
   Clinical epidemiology and treatment outcomes of spindle cell non-osteogenic bone sarcomas - A nationwide population-based study
   J Bone Oncol, 14, 002-2
   DOI 10.1016/j.jbo.2018.11.002, PubMed 30568874
2. Berner K, Zaikova O, Johannesen TB, Hall KS, Bruland ØS (2018)
   Validity and completeness of the Scandinavian Sarcoma Group Central Register by comparison with a nationwide cohort of patients with osteosarcoma in Norway
   J Surg Oncol, 118 (1), 246-247
   DOI 10.1002/jso.25137, PubMed 30208205
3. Boye K, Berner JM, Hompland I, Bruland ØS, Stoldt S, Sundby Hall K, Bjerkehagen B, Hølmebakk T (2018)
   Genotype and risk of tumour rupture in gastrointestinal stromal tumour
   Br J Surg, 105 (2), e169-e175
   DOI 10.1002/bjs.10743, PubMed 29341147
4. Heinrich D, Bruland Ø, Guise TA, Suzuki H, Sartor O (2018)
   Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker
   Future Oncol, 14 (24), 2543-2556
   DOI 10.2217/fon-2018-0087, PubMed 29925281
5. Herlofson BB, Kjølle GK, Westgaard KL, Løndalen AM, Bruland ØS (2018)
   Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223
   Clin Genitourin Cancer, 16 (5), 328-331
   DOI 10.1016/j.clgc.2018.05.003, PubMed 29861164
6. Hesla AC, Bruland ØS, Jebsen N, Styring E, Eriksson S, Tsagozis P (2018)
   Ewing sarcoma of the mobile spine; predictive factors for survival, neurological function and local control. A Scandinavian sarcoma group study with a mean follow-up of 12 years
   J Bone Oncol, 14, 100216
   DOI 10.1016/j.jbo.2018.100216, PubMed 30666289
7. Hompland I, Hølmebakk T, Boye K, Stoldt S, Bjerkehagen B, Berner JM, Wiedswang AM, Revheim ME, Poulsen JP, Hall KS, Bruland ØS (2018)
   [Not Available]
   Tidsskr Nor Laegeforen, 138 (15)
   DOI 10.4045/tidsskr.18.0200, PubMed 30277049
8. Hølmebakk T, Hompland I, Bjerkehagen B, Stoldt S, Bruland ØS, Hall KS, Boye K (2018)
   Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study
   Ann Surg Oncol, 25 (5), 1133-1139
   DOI 10.1245/s10434-018-6353-5, PubMed 29435684
9. Sundby Hall K, Bruland ØS, Bjerkehagen B, Zaikova O, Engellau J, Hagberg O, Hansson L, Hagberg H, Ahlström M, Knobel H, Papworth K, Zemmler M, Goplen D, Bauer HCF, Eriksson M (2018)
   Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX)
   Eur J Cancer, 99, 78-85
   DOI 10.1016/j.ejca.2018.05.011, PubMed 29929092
10. Westrøm S, Bønsdorff TB, Bruland ØS, Larsen RH (2018)
    Therapeutic Effect of α-Emitting ²²⁴Ra-Labeled Calcium Carbonate Microparticles in Mice with Intraperitoneal Ovarian Cancer
    Transl Oncol, 11 (2), 259-267
    DOI 10.1016/j.tranon.2017.12.011, PubMed 29413758
11. Westrøm S, Malenge M, Jorstad IS, Napoli E, Bruland ØS, Bønsdorff TB, Larsen RH (2018)
    Ra-224 labeling of calcium carbonate microparticles for internal α-therapy: Preparation, stability, and biodistribution in mice
    J Labelled Comp Radiopharm, 61 (6), 472-486
    DOI 10.1002/jlcr.3610, PubMed 29380410

Publications 2017

1. Hompland I, Bruland ØS, Hølmebakk T, Poulsen JP, Stoldt S, Hall KS, Boye K (2017)
   Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort
   Acta Oncol, 56 (10), 1317-1323
   DOI 10.1080/0284186X.2017.1330555, PubMed 28557540
2. Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS et al. (2017)
   Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial
   Eur Urol, 73 (3), 427-435
   DOI 10.1016/j.eururo.2017.06.021, PubMed 28705540
3. Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Vogelzang NJ, Bruland Ø, Kobina S, Wilhelm S, Xu L, Shan M, Kattan MW, Parker C (2017)
   An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223
   Ann Oncol, 28 (5), 1090-1097
   DOI 10.1093/annonc/mdx044, PubMed 28453701

Publications 2016

1. Barøy T, Chilamakuri CS, Lorenz S, Sun J, Bruland ØS, Myklebost O, Meza-Zepeda LA (2016)
   Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene
   PLoS One, 11 (9), e0163859
   DOI 10.1371/journal.pone.0163859, PubMed 27685995
2. Hompland I, Bruland ØS, Ubhayasekhera K, Bergquist J, Boye K (2016)
   Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour
   Clin Sarcoma Res, 6, 21
   DOI 10.1186/s13569-016-0062-2, PubMed 27999655
3. Hølmebakk T, Bjerkehagen B, Boye K, Bruland Ø, Stoldt S, Sundby Hall K (2016)
   Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine
   Br J Surg, 103 (6), 684-691
   DOI 10.1002/bjs.10104, PubMed 26988241
4. König M, Osnes TA, Lobmaier I, Bjerkehagen B, Bruland ØS, Sundby Hall K, Meling TR (2016)
   Multimodal treatment of craniofacial osteosarcoma with high-grade histology. A single-center experience over 35 years
   Neurosurg Rev, 40 (3), 449-460
   DOI 10.1007/s10143-016-0802-z, PubMed 27858303
5. Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Bruland Ø, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R, Seger MA, Bottomley D (2016)
   Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial
   Eur Urol, 70 (5), 875-883
   DOI 10.1016/j.eururo.2016.06.002, PubMed 27344296
6. Varghese M, Bruland O, Wiedswang AM, Lobmaier I, Røsok B, Benjamin RS, Hall KS (2016)
   Metastatic mesenteric dedifferentiated leiomyosarcoma: a case report and a review of literature
   Clin Sarcoma Res, 6, 2
   DOI 10.1186/s13569-016-0042-6, PubMed 26913180
7. Westrøm S, Bønsdorff TB, Abbas N, Bruland ØS, Jonasdottir TJ, Mælandsmo GM, Larsen RH (2016)
   Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma
   PLoS One, 11 (10), e0165382
   DOI 10.1371/journal.pone.0165382, PubMed 27776176

Publications 2015

1. Anfinsen KP, Grotmol T, Bruland OS, Cathrine T, Jonasdottir TJ (2015)
   Corrigendum to "Primary bone cancer in Leonbergers may be associated with a higher bodyweight during adolescence" [Prev. Vet. Med. 119 (2015) 48-53]
   Prev Vet Med, 120 (2), 252
   DOI 10.1016/j.prevetmed.2015.03.015, PubMed 31159133
2. Anfinsen KP, Grotmol T, Bruland OS, Trangerud C, Jonasdottir TJ (2015)
   Primary bone cancer in Leonbergers may be associated with a higher bodyweight during adolescence
   Prev Vet Med, 119 (1-2), 48-53
   DOI 10.1016/j.prevetmed.2015.02.003, PubMed 25732913
3. Berner K, Bjerkehagen B, Bruland ØS, Berner A (2015)
   Extraskeletal osteosarcoma in Norway, between 1975 and 2009, and a brief review of the literature
   Anticancer Res, 35 (4), 2129-40
   PubMed 25862869
4. Berner K, Hall KS, Monge OR, Weedon-Fekjær H, Zaikova O, Bruland ØS (2015)
   Prognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient
   Sarcoma, 2015, 516843
   DOI 10.1155/2015/516843, PubMed 25784831
5. Berner K, Johannesen TB, Bruland ØS (2015)
   Clinical Epidemiology of Low-Grade and Dedifferentiated Osteosarcoma in Norway during 1975 and 2009
   Sarcoma, 2015, 917679
   DOI 10.1155/2015/917679, PubMed 26412976
6. Fauske L, Bondevik H, Bruland ØS, Ozakinci G (2015)
   Negative and Positive Consequences of Cancer Treatment Experienced by Long-term Osteosarcoma Survivors: A Qualitative Study
   Anticancer Res, 35 (11), 6081-90
   PubMed 26504033
7. Fauske L, Bruland OS, Grov EK, Bondevik H (2015)
   Cured of primary bone cancer, but at what cost: a qualitative study of functional impairment and lost opportunities
   Sarcoma, 2015, 484196
   DOI 10.1155/2015/484196, PubMed 25949211
8. Hompland I, Bruland ØS (2015)
   Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST?
   Anticancer Res, 35 (11), 5759-65
   PubMed 26503996
9. Humm JL, Sartor O, Parker C, Bruland OS, Macklis R (2015)
   Radium-223 in the treatment of osteoblastic metastases: a critical clinical review
   Int J Radiat Oncol Biol Phys, 91 (5), 898-906
   DOI 10.1016/j.ijrobp.2014.12.061, PubMed 25832684
10. Juzeniene A, Baturaite Z, Lagunova Z, Grigalavicius M, Porojnicu AC, Bruland ØS, Moan J (2015)
    Influence of multiple UV exposures on serum cobalamin and vitamin D levels in healthy females
    Scand J Public Health, 43 (3), 324-30
    DOI 10.1177/1403494815572206, PubMed 25740614
11. Juzeniene A, Porojnicu AC, Baturaite Z, Lagunova Z, Aksnes L, Bruland ØS, Moan J (2015)
    Vitamin D levels and dietary intake among patients with benign soft tissue tumors and sarcomas
    Anticancer Res, 35 (2), 1171-80
    PubMed 25667508

Publications 2014

1. Berner K, Johannesen TB, Berner A, Haugland HK, Bjerkehagen B, Bøhler PJ, Bruland ØS (2014)
   Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma
   Acta Oncol, 54 (1), 25-33
   DOI 10.3109/0284186X.2014.923934, PubMed 24957555
2. Ohnstad HO, Bruland OS, Taksdal I, Bjerkehagen B, Nenadovic M, Sæter G, Jørgensen LH, Hall KS (2014)
   Response to preoperative chemotherapy in patients undergoing resection of pulmonary metastasis from soft tissue sarcoma - a predictor of outcome?
   Acta Oncol, 53 (9), 1180-7
   DOI 10.3109/0284186X.2014.899433, PubMed 24697744
3. Repetto-Llamazares A, Abbas N, Bruland ØS, Dahle J, Larsen RH (2014)
   Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors
   Anticancer Res, 34 (7), 3263-9
   PubMed 24982330
4. Repetto-Llamazares AH, Larsen RH, Giusti AM, Riccardi E, Bruland ØS, Selbo PK, Dahle J (2014)
   177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice
   PLoS One, 9 (7), e103070
   DOI 10.1371/journal.pone.0103070, PubMed 25068508
5. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Bruland ØS, Parker C (2014)
   Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
   Lancet Oncol, 15 (7), 738-46
   DOI 10.1016/S1470-2045(14)70183-4, PubMed 24836273
6. Switlyk MD, Bruland ØS, Skjeldal S, Hald JK, Seierstad T, Zaikova O (2014)
   Radiotherapy for spinal metastases from breast cancer with emphasis on local disease control and pain response using repeated MRI
   J Bone Oncol, 3 (1), 5-9
   DOI 10.1016/j.jbo.2014.02.003, PubMed 26909292

Publications 2013

1. Abbas N, Heyerdahl H, Bruland ØS, Brevik EM, Dahle J (2013)
   Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts
   Curr Radiopharm, 6 (2), 78-86
   DOI 10.2174/18744710113069990017, PubMed 23551110
2. Bjerkehagen B, Småstuen MC, Hall KS, Skjeldal S, Bruland ØS, Smeland S, Johannesen TB, Fosså SD (2013)
   Incidence and mortality of second sarcomas - a population-based study
   Eur J Cancer, 49 (15), 3292-302
   DOI 10.1016/j.ejca.2013.05.017, PubMed 23787025
3. Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH (2013)
   Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma
   Anticancer Res, 33 (1), 85-95
   PubMed 23267131
4. Fløisand Y, Beiske K, Tjønnfjord GE, Heldal D, Bjerkehagen B, Revheim ME, Heim S, Bruland OS, Hall KS, Tierens A, Delabie J (2013)
   Malignant phyllodes tumor and acute megakaryoblastic leukemia sharing a common clonal origin
   Case Rep Hematol, 2013, 934781
   DOI 10.1155/2013/934781, PubMed 24455338
5. Heyerdahl H, Abbas N, Sponheim K, Mollatt C, Bruland Ø, Dahle J (2013)
   Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice
   Curr Radiopharm, 6 (2), 106-16
   DOI 10.2174/18744710113069990018, PubMed 23551111
6. Jebsen NL, Engellau J, Engström K, Bauer HC, Monge OR, Muren LP, Eide GE, Trovik CS, Bruland OS (2013)
   Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall
   Int J Radiat Oncol Biol Phys, 86 (5), 949-55
   DOI 10.1016/j.ijrobp.2013.04.015, PubMed 23725998
7. Lagunova Z, Porojnicu AC, Aksnes L, Holick MF, Iani V, Bruland OS, Moan J (2013)
   Effect of vitamin D supplementation and ultraviolet B exposure on serum 25-hydroxyvitamin D concentrations in healthy volunteers: a randomized, crossover clinical trial
   Br J Dermatol, 169 (2), 434-40
   DOI 10.1111/bjd.12349, PubMed 23551243
8. Lia K, Bruland ØS, Randem HL, Aksnes LH, Poulsen JP, Taksdal I, Sundby Hall K (2013)
   Two cases with fatal outcome following total lung irradiation for metastatic bone sarcoma
   J Bone Oncol, 2 (4), 174-9
   DOI 10.1016/j.jbo.2013.09.002, PubMed 26909289
9. Mikalsen LT, Dhakal HP, Bruland ØS, Naume B, Borgen E, Nesland JM, Olsen DR (2013)
   The clinical impact of mean vessel size and solidity in breast carcinoma patients
   PLoS One, 8 (10), e75954
   DOI 10.1371/journal.pone.0075954, PubMed 24146798
10. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG et al. (2013)
    Alpha emitter radium-223 and survival in metastatic prostate cancer
    N Engl J Med, 369 (3), 213-23
    DOI 10.1056/NEJMoa1213755, PubMed 23863050
11. Revheim ME, Hole KH, Bruland OS, Reitan E, Bjerkehagen B, Julsrud L, Seierstad T (2013)
    Multimodal functional imaging for early response assessment in GIST patients treated with imatinib
    Acta Oncol, 53 (1), 143-8
    DOI 10.3109/0284186X.2013.798428, PubMed 23710697
12. Revheim ME, Kristian A, Malinen E, Bruland ØS, Berner JM, Holm R, Joensuu H, Seierstad T (2013)
    Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
    Acta Oncol, 52 (4), 776-82
    DOI 10.3109/0284186X.2013.770920, PubMed 23480638
13. Rusten E, Rødal J, Bruland Ø, Malinen E (2013)
    Biologic targets identified from dynamic 18FDG-PET and implications for image-guided therapy
    Acta Oncol, 52 (7), 1378-83
    DOI 10.3109/0284186X.2013.813071, PubMed 23981046

Publications 2012

1. Abbas N, Bruland ØS, Brevik EM, Dahle J (2012)
   Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts
   Nucl Med Commun, 33 (8), 838-47
   DOI 10.1097/MNM.0b013e328354df7c, PubMed 22643311
2. Micu E, Baturaite Z, Juzeniene A, Bruland ØS, Moan JE (2012)
   Superficial-spreading and nodular melanomas in Norway: a comparison by body site distribution and latitude gradients
   Melanoma Res, 22 (6), 460-5
   DOI 10.1097/CMR.0b013e3283599cc3, PubMed 23010822
3. Namløs HM, Kresse SH, Müller CR, Henriksen J, Holdhus R, Sæter G, Bruland OS, Bjerkehagen B, Steen VM, Myklebost O (2012)
   Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern
   Sarcoma, 2012, 639038
   DOI 10.1155/2012/639038, PubMed 22518090
4. Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernäs B, Petersson U, Johannessen DC, Sokal M, Pigott K, O'Bryan-Tear CG, Thuresson M, Bolstad B, Bruland ØS (2012)
   Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases
   Clin Genitourin Cancer, 11 (1), 20-6
   DOI 10.1016/j.clgc.2012.07.002, PubMed 23021204
5. Nilsson S, Strang P, Aksnes AK, Franzèn L, Olivier P, Pecking A, Staffurth J, Vasanthan S, Andersson C, Bruland ØS (2012)
   A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
   Eur J Cancer, 48 (5), 678-86
   DOI 10.1016/j.ejca.2011.12.023, PubMed 22341993
6. Rusten E, Rødal J, Revheim ME, Skretting A, Bruland OS, Malinen E (2012)
   Quantitative dynamic ¹⁸FDG-PET and tracer kinetic analysis of soft tissue sarcomas
   Acta Oncol, 52 (6), 1160-7
   DOI 10.3109/0284186X.2012.728713, PubMed 23198721
7. Sartor O, Hoskin P, Bruland OS (2012)
   Targeted radio-nuclide therapy of skeletal metastases
   Cancer Treat Rev, 39 (1), 18-26
   DOI 10.1016/j.ctrv.2012.03.006, PubMed 22534284

Publications 2011

1. Abbas N, Heyerdahl H, Bruland OS, Borrebæk J, Nesland J, Dahle J (2011)
   Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab
   EJNMMI Res, 1 (1), 18
   DOI 10.1186/2191-219X-1-18, PubMed 22214432
2. Anfinsen KP, Devesa SS, Bray F, Troisi R, Jonasdottir TJ, Bruland OS, Grotmol T (2011)
   Age-period-cohort analysis of primary bone cancer incidence rates in the United States (1976-2005)
   Cancer Epidemiol Biomarkers Prev, 20 (8), 1770-7
   DOI 10.1158/1055-9965.EPI-11-0136, PubMed 21724855
3. Anfinsen KP, Grotmol T, Bruland OS, Jonasdottir TJ (2011)
   Breed-specific incidence rates of canine primary bone tumors--a population based survey of dogs in Norway
   Can J Vet Res, 75 (3), 209-15
   PubMed 22210997
4. Dahle J, Abbas N, Bruland ØS, Larsen RH (2011)
   Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates
   Curr Radiopharm, 4 (4), 321-8
   DOI 10.2174/1874471011104040321, PubMed 22202154
5. Mikalsen LT, Dhakal HP, Bruland OS, Nesland JM, Olsen DR (2011)
   Quantification of angiogenesis in breast cancer by automated vessel identification in CD34 immunohistochemical sections
   Anticancer Res, 31 (12), 4053-60
   PubMed 22199261
6. Revheim ME, Røe K, Bruland ØS, Bach-Gansmo T, Skretting A, Seierstad T (2011)
   Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT
   Mol Imaging Biol, 13 (6), 1234-40
   DOI 10.1007/s11307-010-0464-0, PubMed 21161686
7. Sartor O, Bruland O (2011)
   Stromal targeted therapies in prostate and renal cancer: new concepts and knowledge
   Clin Genitourin Cancer, 9 (1), 1-2
   DOI 10.1016/j.clgc.2011.08.001, PubMed 21925102
8. Sartor O, Goeckeler W, Bruland O (2011)
   Stromal targeted therapy in bone metastatic prostate cancer: promise delivered
   Asian J Androl, 13 (6), 783-4
   DOI 10.1038/aja.2011.120, PubMed 21857688
9. Smeland S, Bruland OS, Hjorth L, Brosjö O, Bjerkehagen B, Osterlundh G, Jakobson A, Hall KS, Monge OR, Björk O, Alvegaard TA (2011)
   Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years
   Acta Orthop, 82 (2), 211-6
   DOI 10.3109/17453674.2011.566141, PubMed 21434784
10. Zaikova O, Fosså SD, Bruland OS, Giercksky KE, Sandstad B, Skjeldal S (2011)
    Radiotherapy or surgery for spine metastases?
    Acta Orthop, 82 (3), 365-71
    DOI 10.3109/17453674.2011.566142, PubMed 21434789

Publications 2010

1. Cicarma E, Juzeniene A, Porojnicu AC, Bruland ØS, Moan J (2010)
   Latitude gradient for melanoma incidence by anatomic site and gender in Norway 1966-2007
   J Photochem Photobiol B, 101 (2), 174-8
   DOI 10.1016/j.jphotobiol.2010.04.002, PubMed 20430639
2. Dale E, Hårsaker V, Kristoffersen DT, Bruland O, Olsen DR (2010)
   CT density in lung cancer patients after radiotherapy sensitized by metoclopramide. A subgroup analysis of a randomized trial
   Strahlenther Onkol, 186 (3), 163-8
   DOI 10.1007/s00066-010-2040-6, PubMed 20165821
3. Jebsen NL, Bruland ØS, Eriksson M, Engellau J, Turesson I, Folin A, Trovik CS, Hall KS (2010)
   Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall
   Int J Radiat Oncol Biol Phys, 81 (5), 1359-66
   DOI 10.1016/j.ijrobp.2010.07.037, PubMed 20933339
4. Lagunova Z, Porojnicu AC, Grant WB, Bruland Ø, Moan JE (2010)
   Obesity and increased risk of cancer: does decrease of serum 25-hydroxyvitamin D level with increasing body mass index explain some of the association?
   Mol Nutr Food Res, 54 (8), 1127-33
   DOI 10.1002/mnfr.200900512, PubMed 20512788
5. Moan J, Lagunova Z, Bruland O, Juzeniene A (2010)
   Seasonal variations of cancer incidence and prognosis
   Dermatoendocrinol, 2 (2), 55-7
   DOI 10.4161/derm.2.2.12664, PubMed 21547098
6. Revheim ME, Hole KH, Bruland OS, Haugland HK, Hall KS, Seierstad T (2010)
   DW MRI for evaluation of treatment response to imatinib in a rectal gastrointestinal stromal tumour
   Acta Oncol, 50 (1), 148-50
   DOI 10.3109/0284186X.2010.516273, PubMed 21110775

Publications 2009

1. Berg A, Dahl AA, Bruland ØS, Bjøro T, Aanensen MS, Fosså SD (2009)
   Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes
   Prostate Cancer Prostatic Dis, 12 (3), 269-76
   DOI 10.1038/pcan.2009.8, PubMed 19290019
2. Brandal P, Bjerkehagen B, Bruland OS, Skjeldal S, Bogsrud TV, Hall KS (2009)
   Synchronous and metachronous skeletal osteosarcomas: the Norwegian Radium Hospital experience
   Acta Oncol, 48 (8), 1165-72
   DOI 10.3109/02841860903032809, PubMed 19863225
3. Bruland ØS, Bauer H, Alvegaard T, Smeland S (2009)
   Treatment of osteosarcoma. The Scandinavian Sarcoma Group experience
   Cancer Treat Res, 152, 309-18
   DOI 10.1007/978-1-4419-0284-9_16, PubMed 20213398
4. Bruland ØS, Høifødt H, Hall KS, Smeland S, Fodstad Ø (2009)
   Bone marrow micrometastases studied by an immunomagnetic isolation procedure in extremity localized non-metastatic osteosarcoma patients
   Cancer Treat Res, 152, 509-15
   DOI 10.1007/978-1-4419-0284-9_30, PubMed 20213412
5. Hall KS, Eriksson M, Bruland OS, Engellau J, Trovik CS (2009)
   Treatment of soft tissue sarcoma of the extremity and trunk wall The Scandinavian Sarcoma Group perspective
   Acta Orthop., 80 334, 52-59
6. Norum OJ, Bruland ØS, Gorunova L, Berg K (2009)
   Photochemical internalization of bleomycin before external-beam radiotherapy improves locoregional control in a human sarcoma model
   Int J Radiat Oncol Biol Phys, 75 (3), 878-85
   DOI 10.1016/j.ijrobp.2009.04.039, PubMed 19665318
7. Revheim ME, Seierstad T, Berner JM, Bruland OS, Røe K, Ohnstad HO, Bjerkehagen B, Bach-Gansmo T (2009)
   Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice
   Anticancer Res, 29 (11), 4331-6
   PubMed 20032375
8. Sande TA, Ruenes R, Lund JA, Bruland OS, Hornslien K, Bremnes R, Kaasa S (2009)
   Long-term follow-up of cancer patients receiving radiotherapy for bone metastases: results from a randomised multicentre trial
   Radiother Oncol, 91 (2), 261-6
   DOI 10.1016/j.radonc.2009.02.014, PubMed 19307034
9. Schwarz R, Bruland O, Cassoni A, Schomberg P, Bielack S (2009)
   The role of radiotherapy in oseosarcoma
   Cancer Treat Res, 152, 147-64
   DOI 10.1007/978-1-4419-0284-9_7, PubMed 20213389
10. Smeland S, Bruland OS, Hjorth L, Brosjo O, Bjerkehagen B, Osterlundh G, Jakobson A, Hall KS, Monge OR, Bjork O, Alvegaard TA (2009)
    Scandinavian experience in classical osteosarcoma Results of the SSG XIV protocol
    Acta Orthop., 80 334, 60-66
11. Søvik S, Skogmo HK, Andersen EK, Bruland ØS, Olsen DR, Malinen E (2009)
    DCEMRI of spontaneous canine tumors during fractionated radiotherapy: a pharmacokinetic analysis
    Radiother Oncol, 93 (3), 618-24
    DOI 10.1016/j.radonc.2009.08.012, PubMed 19747746

Publications 2008

1. Berg A, Bruland ØS, Fosså SD, Nesland JM, Berner A, Schirmer C, Lilleby W (2008)
   Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer
   Prostate, 68 (15), 1607-14
   DOI 10.1002/pros.20826, PubMed 18655095
2. Bruland OS, Jonasdottir TJ, Fisher DR, Larsen RH (2008)
   Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy
   Curr. Radiopharm., 1 (3), 203-208
   DOI 10.2174/1874471010801030203
3. Dahle J, Bruland OS, Larsen RH (2008)
   Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation
   Int J Radiat Oncol Biol Phys, 72 (1), 186-92
   DOI 10.1016/j.ijrobp.2008.05.029, PubMed 18722269
4. Erikson A, Tufto I, Bjønnum AB, Bruland ØS, Davies Cde L (2008)
   The impact of enzymatic degradation on the uptake of differently sized therapeutic molecules
   Anticancer Res, 28 (6A), 3557-66
   PubMed 19189635
5. Jebsen NL, Trovik CS, Bauer HC, Rydholm A, Monge OR, Hall KS, Alvegård T, Bruland OS (2008)
   Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian sarcoma group study
   Int J Radiat Oncol Biol Phys, 71 (4), 1196-203
   DOI 10.1016/j.ijrobp.2007.11.023, PubMed 18207661
6. Porojnicu AC, Bruland OS, Aksnes L, Grant WB, Moan J (2008)
   Sun beds and cod liver oil as vitamin D sources
   J Photochem Photobiol B, 91 (2-3), 125-31
   DOI 10.1016/j.jphotobiol.2008.02.007, PubMed 18417354
7. Søvik A, Kippenes Skogmo H, Bruland ØS, Rune Olsen D, Malinen E (2008)
   DCEMRI monitoring of canine tumors during fractionated radiotherapy
   Acta Oncol, 47 (7), 1249-56
   DOI 10.1080/02841860802244166, PubMed 18618342
8. Vågane R, Bruland ØS, Fosså SD, Olsen DR (2008)
   Radiological and functional assessment of radiation-induced pulmonary damage following breast irradiation
   Acta Oncol, 47 (2), 248-54
   DOI 10.1080/02841860701630267, PubMed 18210300

Publications 2007

1. Aksnes LH, Bruland ØS (2007)
   Some musculo-skeletal sequelae in cancer survivors
   Acta Oncol, 46 (4), 490-6
   DOI 10.1080/02841860701218642, PubMed 17497316
2. Berg A, Berner A, Lilleby W, Bruland ØS, Fosså SD, Nesland JM, Kvalheim G (2007)
   Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy
   Int J Cancer, 120 (8), 1603-9
   DOI 10.1002/ijc.22488, PubMed 17230512
3. Berg A, Lilleby W, Bruland OS, Fosså SD (2007)
   10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy
   Int J Radiat Oncol Biol Phys, 69 (4), 1074-83
   DOI 10.1016/j.ijrobp.2007.04.031, PubMed 17703896
4. Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland ØS, Press OW, Larsen RH (2007)
   Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate
   Blood, 110 (6), 2049-56
   DOI 10.1182/blood-2007-01-066803, PubMed 17536011
5. Larsen RH, Borrebaek J, Dahle J, Melhus KB, Krogh C, Valan MH, Bruland OS (2007)
   Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability
   Cancer Biother Radiopharm, 22 (3), 431-7
   DOI 10.1089/cbr.2006.321, PubMed 17651051
6. Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernäs B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS (2007)
   Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
   Lancet Oncol, 8 (7), 587-94
   DOI 10.1016/S1470-2045(07)70147-X, PubMed 17544845
7. Olsen DR, Bruland OS, Frykholm G, Norderhaug IN (2007)
   Proton therapy - a systematic review of clinical effectiveness
   Radiother Oncol, 83 (2), 123-32
   DOI 10.1016/j.radonc.2007.03.001, PubMed 17499374
8. Porojnicu AC, Robsahm TE, Dahlback A, Berg JP, Christiani D, Bruland OS, Moan J (2007)
   Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role?
   Lung Cancer, 55 (3), 263-70
   DOI 10.1016/j.lungcan.2006.11.013, PubMed 17207891
9. Søvik A, Malinen E, Skogmo HK, Bentzen SM, Bruland OS, Olsen DR (2007)
   Radiotherapy adapted to spatial and temporal variability in tumor hypoxia
   Int J Radiat Oncol Biol Phys, 68 (5), 1496-504
   DOI 10.1016/j.ijrobp.2007.04.027, PubMed 17674980

Publications 2006

1. Aksnes LH, Hall KS, Folleraas G, Stenwig AE, Bjerkehagen B, Taksdal I, Winderen M, Bruland OS, Saeter G (2006)
   Management of high-grade bone sarcomas over two decades: the Norwegian Radium Hospital experience
   Acta Oncol, 45 (1), 38-46
   DOI 10.1080/02841860500466624, PubMed 16464794
2. Bruland ØS (2006)
   [Jumping after the Swedes]
   Tidsskr Nor Laegeforen, 126 (5), 637
   PubMed 16505887
3. Bruland ØS, Nilsson S, Fisher DR, Larsen RH (2006)
   High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
   Clin Cancer Res, 12 (20 Pt 2), 6250s-6257s
   DOI 10.1158/1078-0432.CCR-06-0841, PubMed 17062709
4. Dahle J, Borrebaek J, Melhus KB, Bruland OS, Salberg G, Olsen DR, Larsen RH (2006)
   Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy
   Nucl Med Biol, 33 (2), 271-9
   DOI 10.1016/j.nucmedbio.2005.12.004, PubMed 16546683
5. Jonasdottir TJ, Fisher DR, Borrebaek J, Bruland OS, Larsen RH (2006)
   First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent
   Anticancer Res, 26 (4B), 2841-8
   PubMed 16886603
6. Kaasa S, Brenne E, Lund JA, Fayers P, Falkmer U, Holmberg M, Lagerlund M, Bruland O (2006)
   Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases
   Radiother Oncol, 79 (3), 278-84
   DOI 10.1016/j.radonc.2006.05.006, PubMed 16793154
7. Larsen RH, Saxtorph H, Skydsgaard M, Borrebaek J, Jonasdottir TJ, Bruland OS, Klastrup S, Harling R, Ramdahl T (2006)
   Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: histology, clinical chemistry and hematology
   In Vivo, 20 (3), 325-31
   PubMed 16724665
8. Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L (2006)
   Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference
   Clin Cancer Res, 12 (20 Pt 2), 6209s-6212s
   DOI 10.1158/1078-0432.CCR-06-1213, PubMed 17062702
9. Malinen E, Søvik A, Hristov D, Bruland ØS, Olsen DR (2006)
   Adapting radiotherapy to hypoxic tumours
   Phys Med Biol, 51 (19), 4903-21
   DOI 10.1088/0031-9155/51/19/012, PubMed 16985278
10. Søvik A, Malinen E, Bruland ØS, Bentzen SM, Olsen DR (2006)
    Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study
    Phys Med Biol, 52 (2), 499-513
    DOI 10.1088/0031-9155/52/2/013, PubMed 17202629

Publications 2005

1. Bruland OS, Høifødt H, Saeter G, Smeland S, Fodstad O (2005)
   Hematogenous micrometastases in osteosarcoma patients
   Clin Cancer Res, 11 (13), 4666-73
   DOI 10.1158/1078-0432.CCR-05-0165, PubMed 16000559
2. Brustugun OT, Reed W, Poulsen JP, Bruland OS (2005)
   Primary osteosarcoma of the breast
   Acta Oncol, 44 (7), 767-70
   DOI 10.1080/02841860500254897, PubMed 16227171
3. Dale E, Hellebust TP, Bruland ØS, Olsen DR (2005)
   Comparative analyses of the dynamic properties of the bladder wall studied by repetitive pelvic CT scans of patients and cryo-sections of cadavers
   Br J Radiol, 78 (930), 528-32
   DOI 10.1259/bjr/82990907, PubMed 15900058
4. Eikenes L, Tari M, Tufto I, Bruland OS, de Lange Davies C (2005)
   Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts
   Br J Cancer, 93 (1), 81-8
   DOI 10.1038/sj.bjc.6602626, PubMed 15942637
5. Henriksen G, Bruland OS, Larsen RH (2005)
   Preparation and preclinical assessment of folate-conjugated, radiolabelled antibodies
   Anticancer Res, 25 (1A), 9-15
   PubMed 15816513
6. Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS (2005)
   First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases
   Clin Cancer Res, 11 (12), 4451-9
   DOI 10.1158/1078-0432.CCR-04-2244, PubMed 15958630
7. Norum J, Bruland ØS, Spanne O, Bergmo T, Green T, Olsen DR, Olsen JH, Sjåeng EE, Burkow T (2005)
   Telemedicine in radiotherapy: a study exploring remote treatment planning, supervision and economics
   J Telemed Telecare, 11 (5), 245-50
   DOI 10.1258/1357633054471858, PubMed 16035967
8. Onda M, Bruland ØS, Pastan I (2005)
   TP-3 immunotoxins improve antitumor activity in mice with osteosarcoma
   Clin Orthop Relat Res (430), 142-8
   DOI 10.1097/01.blo.0000137544.30200.b6, PubMed 15662316

Publications 2004

1. Bruheim S, Bruland OS, Breistol K, Maelandsmo GM, Fodstad O (2004)
   Human osteosarcoma xenografts and their sensitivity to chemotherapy
   Pathol Oncol Res, 10 (3), 133-41
   DOI 10.1007/BF03033741, PubMed 15448748
2. Eikenes L, Bruland ØS, Brekken C, Davies Cde L (2004)
   Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts
   Cancer Res, 64 (14), 4768-73
   DOI 10.1158/0008-5472.CAN-03-1472, PubMed 15256445
3. Henriksen G, Bruland OS, Larsen RH (2004)
   Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents
   Anticancer Res, 24 (1), 101-5
   PubMed 15015582
4. Henriksen G, Schoultz BW, Michaelsen TE, Bruland ØS, Larsen RH (2004)
   Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides
   Nucl Med Biol, 31 (4), 441-9
   DOI 10.1016/j.nucmedbio.2003.11.004, PubMed 15093814
5. Mikkelsen IM, Løkke C, Flagstad T, Bruland ØS (2004)
   Interferon-γ Sensitises Human Osteosarcoma Cells to Trail-mediated Apoptosis
   Cancer Genomics Proteomics, 1 (2), 95-104
   PubMed 31394674

Publications 2003

1. Dale E, Hellebust TP, Bruland ØS, Olsen DR (2003)
   Comparative analyses of the dynamic properties of the rectum studied by cryo-sections of human cadavers and pelvic CT scans of patients
   Br J Radiol, 76 (902), 104-8
   DOI 10.1259/bjr/75640835, PubMed 12642278
2. Henriksen G, Fisher DR, Roeske JC, Bruland ØS, Larsen RH (2003)
   Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice
   J Nucl Med, 44 (2), 252-9
   PubMed 12571218
3. Olstad OK, Gautvik VT, Reppe S, Rian E, Jemtland R, Ohlsson C, Bruland OS, Gautvik KM (2003)
   Molecular heterogeneity in human osteosarcoma demonstrated by enriched mRNAs isolated by directional tag PCR subtraction cloning
   Anticancer Res, 23 (3B), 2201-16
   PubMed 12894494

Publications 2002

1. Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, Smithson WA, Mullan BP, Bruland OS (2002)
   High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases
   J Clin Oncol, 20 (1), 189-96
   DOI 10.1200/JCO.2002.20.1.189, PubMed 11773169
2. Aurlien E, Kvinnsland Y, Larsen RH, Bruland ØS (2002)
   Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation
   Int J Radiat Biol, 78 (2), 133-42
   DOI 10.1080/09553000110094788, PubMed 11779363
3. Henriksen G, Breistøl K, Bruland ØS, Fodstad Ø, Larsen RH (2002)
   Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model
   Cancer Res, 62 (11), 3120-5
   PubMed 12036923
4. Kvinnsland Y, Bruland O, Moe L, Skretting A (2002)
   A method for measurement of the uptake patterns of two beta-emitting radionuclides in the same tissue section with a digital silicon detector: application to a study of 89SrCl2 and 153Sm-EDTMP in a dog with spontaneous osteosarcoma
   Eur J Nucl Med Mol Imaging, 29 (2), 191-7
   DOI 10.1007/s00259-001-0693-1, PubMed 11926381
5. Ree AH, Bratland A, Kroes RA, Aasheim HC, Flørenes VA, Moskal JR, Fodstad O, Bruland OS, Maelandsmo GM (2002)
   Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases
   Anticancer Res, 22 (4), 1949-57
   PubMed 12174869
6. Saeter G, Hall KS, Bruland ØS, Solheim ØP, Høie J, Follerås G, Helgerud P, Stenwig AE, Bjerkehagen B, Talle K, Taksdal I, Winderen M (2002)
   [Bone and soft tissue sarcomas treated at the Norwegian Radium Hospital 1980-99]
   Tidsskr Nor Laegeforen, 122 (21), 2089-94
   PubMed 12555642

Publications 2001

1. Hassfjell S, Ingebrigtsen K, Bruland ØS (2001)
   Synthesis, purification and biodistribution of (205)Bi-DOTMP, visualizing bone deposition patterns with autoradiography
   Nucl Med Biol, 28 (4), 425-33
   DOI 10.1016/s0969-8051(01)00202-5, PubMed 11395316
2. Kvinnsland Y, Skretting A, Bruland OS (2001)
   Radionuclide therapy with bone-seeking compounds: Monte Carlo calculations of dose-volume histograms for bone marrow in trabecular bone
   Phys Med Biol, 46 (4), 1149-61
   DOI 10.1088/0031-9155/46/4/317, PubMed 11324957
3. Onda M, Olafsen T, Tsutsumi Y, Bruland OS, Pastan I (2001)
   Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A
   J Immunother, 24 (2), 144-50
   DOI 10.1097/00002371-200103000-00009, PubMed 11265772

Publications 2000

1. Aurlien E, Larsen RH, Akabani G, Olsen DR, Zalutsky MR, Bruland OS (2000)
   Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry
   Int J Radiat Biol, 76 (8), 1129-41
   DOI 10.1080/09553000050111604, PubMed 10947126
2. Aurlien E, Larsen RH, Kvalheim G, Bruland OS (2000)
   Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells
   Br J Cancer, 83 (10), 1375-9
   DOI 10.1054/bjoc.2000.1453, PubMed 11044364
3. Braendengen M, Bruland OS, Olsen DR (2000)
   [Radiotherapy of skeletal metastases]
   Tidsskr Nor Laegeforen, 120 (16), 1870-4
   PubMed 10925615
4. Brekken C, Bruland ØS, de Lange Davies C (2000)
   Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase
   Anticancer Res, 20 (5B), 3503-12
   PubMed 11131654
5. Brekken C, Hjelstuen MH, Bruland ØS, de Lange Davies C (2000)
   Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts
   Anticancer Res, 20 (5B), 3513-9
   PubMed 11131655
6. Pihl A, Bruland OS (2000)
   Oral presentations in science and medicine. An art in decline?
   Anticancer Res, 20 (5A), 2795-9
   PubMed 11062686

Publications 1999

1. Jemtland R, Rian E, Olstad OK, Haug E, Bruland OS, Bucht E, Gautvik KM (1999)
   Two human osteoblast-like osteosarcoma cell lines show distinct expression and differential regulation of parathyroid hormone-related protein
   J Bone Miner Res, 14 (6), 904-14
   DOI 10.1359/jbmr.1999.14.6.904, PubMed 10352098
2. Larsen RH, Murud KM, Akabani G, Hoff P, Bruland OS, Zalutsky MR (1999)
   211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation
   J Nucl Med, 40 (7), 1197-203
   PubMed 10405142
3. Murud KM, Larsen RH, Bruland OS, Hoff P (1999)
   Influence of pretreatment with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APB) on organ uptake of 211At and 125I-labeled amidobisphosphonates in mice
   Nucl Med Biol, 26 (7), 791-4
   DOI 10.1016/s0969-8051(99)00047-5, PubMed 10628558
4. Olafsen T, Munthe Lund CK, Bruland OS, Sandlie I, Michaelsen TE (1999)
   Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies
   Cancer Immunol Immunother, 48 (7), 411-8
   DOI 10.1007/s002620050594, PubMed 10501855
5. Ree AH, Tvermyr M, Engebraaten O, Rooman M, Røsok O, Hovig E, Meza-Zepeda LA, Bruland OS, Fodstad O (1999)
   Expression of a novel factor in human breast cancer cells with metastatic potential
   Cancer Res, 59 (18), 4675-80
   PubMed 10493524
6. Tanum G, Bruland OS, Hjelle D, Reitan JB (1999)
   [Patient treatment in radiation accidents]
   Tidsskr Nor Laegeforen, 119 (10), 1446-50
   PubMed 10354753
7. Aas M, Moe L, Gamlem H, Skretting A, Ottesen N, Bruland OS (1999)
   Internal radionuclide therapy of primary osteosarcoma in dogs, using 153Sm-ethylene-diamino-tetramethylene-phosphonate (EDTMP)
   Clin Cancer Res, 5 (10 Suppl), 3148s-3152s
   PubMed 10541356

Publications 1998

1. Hassfjell SP, Skretting A, Bruland OS, Hoff P (1998)
   Predicting detectability in radioguided surgery: a study based on physical characterization of the probe and on tissue uptake ratios of 125I-, 153Sm- and 165Er-labelled radiopharmaceuticals
   Nucl Med Commun, 19 (3), 207-17
   DOI 10.1097/00006231-199803000-00004, PubMed 9625495
2. Larsen RH, Bruland OS (1998)
   Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay
   Br J Cancer, 77 (7), 1115-22
   DOI 10.1038/bjc.1998.185, PubMed 9569048
3. Lopes JM, Hannisdal E, Bjerkehagen B, Bruland OS, Danielsen HE, Pettersen EO, Sobrinho-Simões M, Nesland JM (1998)
   Synovial sarcoma. Evaluation of prognosis with emphasis on the study of DNA ploidy and proliferation (PCNA and Ki-67) markers
   Anal Cell Pathol, 16 (1), 45-62
   DOI 10.1155/1998/545906, PubMed 9584899
4. Olafsen T, Rasmussen IB, Norderhaug L, Bruland OS, Sandlie I (1998)
   IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells
   Immunotechnology, 4 (2), 141-53
   DOI 10.1016/s1380-2933(98)00014-1, PubMed 9853955
5. Olsen DR, Bruland OS (1998)
   Radiotherapy in Scandinavia
   Acta Oncol, 37 (6), 553-60
   DOI 10.1080/028418698430250, PubMed 9860313

Publications 1997

1. Bruland OS, Pihl A (1997)
   On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy
   Eur J Cancer, 33 (11), 1725-31
   DOI 10.1016/s0959-8049(97)00252-9, PubMed 9470825
2. Ekstrøm PO, Giercksky KE, Andersen A, Bruland OS, Slørdal L (1997)
   Intratumoral differences in methotrexate levels within human osteosarcoma xenografts studied by microdialysis
   Life Sci, 61 (19), PL275-80
   DOI 10.1016/s0024-3205(97)00839-4, PubMed 9364204
3. Hassfjell SP, Bruland OS, Hoff P (1997)
   212Bi-DOTMP: an alpha particle emitting bone-seeking agent for targeted radiotherapy
   Nucl Med Biol, 24 (3), 231-7
   DOI 10.1016/s0969-8051(97)00059-0, PubMed 9228657
4. Lopes JM, Bruland OS, Bjerkehagen B, Silva MC, Holm R, Pettersen EO, Solheim OP, Sobrinho-Simões M, Nesland JM (1997)
   Synovial sarcoma: immunohistochemical expression of P-glycoprotein and glutathione S transferase-pi and clinical drug resistance
   Pathol Res Pract, 193 (1), 21-36
   DOI 10.1016/s0344-0338(97)80090-8, PubMed 9112270

Publications 1996

1. Bruland OS, Skretting A, Solheim OP, Aas M (1996)
   Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach
   Acta Oncol, 35 (3), 381-4
   DOI 10.3109/02841869609101655, PubMed 8679270
2. Gordeladze JO, Lund HW, Jablonski G, Bruland OS (1996)
   Diverse expression of G-proteins in human sarcoma cell lines with different osteogenic potential: evidence for the involvement of Gi2 in cell proliferation
   J Cell Biochem, 60 (1), 95-106
   DOI 10.1002/(SICI)1097-4644(19960101)60:1%3C95::AID-JCB12%3E3.0.CO;2-J, PubMed 8825419
3. Moe L, Boysen M, Aas M, Lønaas L, Gamlem H, Bruland OS (1996)
   Maxillectomy and targeted radionuclide therapy with 153Sm-EDTMP in a recurrent canine osteosarcoma
   J Small Anim Pract, 37 (5), 241-6
   DOI 10.1111/j.1748-5827.1996.tb01782.x, PubMed 8736231
4. Olafsen T, Bruland OS, Zalutsky MR, Sandlie I (1996)
   Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling
   Acta Oncol, 35 (3), 297-301
   DOI 10.3109/02841869609101644, PubMed 8679259
5. Saeter G, Bruland OS, Follerås G, Boysen M, Høie J (1996)
   Extremity and non-extremity high-grade osteosarcoma -- the Norwegian Radium Hospital experience during the modern chemotherapy era
   Acta Oncol, 35 Suppl 8, 129-34
   DOI 10.3109/02841869609098531, PubMed 9073059

Publications 1995

1. Bruland OS (1995)
   Cancer therapy with radiolabeled antibodies. An overview
   Acta Oncol, 34 (8), 1085-94
   DOI 10.3109/02841869509127235, PubMed 8608033
2. Larsen RH, Hoff P, Vergote IB, Bruland OS, Aas M, De Vos L, Nustad K (1995)
   Alpha-particle radiotherapy with 211At-labeled monodisperse polymer particles, 211At-labeled IgG proteins, and free 211At in a murine intraperitoneal tumor model
   Gynecol Oncol, 57 (1), 9-15
   DOI 10.1006/gyno.1995.1093, PubMed 7705707
3. Olafsen T, Bruland OS, Zalutsky MR, Sandlie I (1995)
   Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: location of lysine residues and implications for radiolabeling
   Nucl Med Biol, 22 (6), 765-71
   DOI 10.1016/0969-8051(95)00014-o, PubMed 8535337

Publications 1994

1. Bruland OS, Fodstad O, Aas M, Solheim OP, Høie J, Skretting A, Winderen M, Michaelsen T, Pihl A (1994)
   Immunoscintigraphy of bone sarcomas--results in 5 patients
   Eur J Cancer, 30A (10), 1484-9
   DOI 10.1016/0959-8049(94)00304-n, PubMed 7833107
2. Larsen RH, Bruland OS, Hoff P, Alstad J, Lindmo T, Rofstad EK (1994)
   Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays
   Radiat Res, 139 (2), 178-84
   DOI 10.2307/3578662, PubMed 8052693
3. Larsen RH, Bruland OS, Hoff P, Alstad J, Rofstad EK (1994)
   Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody
   Br J Cancer, 69 (6), 1000-5
   DOI 10.1038/bjc.1994.196, PubMed 8198960
4. Page RL, Garg PK, Garg S, Archer GE, Bruland OS, Zalutsky MR (1994)
   PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment
   J Nucl Med, 35 (9), 1506-13
   PubMed 8071702

Publications 1993

1. Andreassen A, Oyjord T, Hovig E, Holm R, Flørenes VA, Nesland JM, Myklebost O, Høie J, Bruland OS, Børresen AL (1993)
   p53 abnormalities in different subtypes of human sarcomas
   Cancer Res, 53 (3), 468-71
   PubMed 8425179

Publications 1992

1. Flørenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O (1992)
   Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression
   Cancer Res, 52 (21), 6088-91
   PubMed 1356624
2. Haines DM, Bruland OS, Matte G, Wilkinson AA, Meric SM, Fowler JD (1992)
   Immunoscintigraphic detection of primary and metastatic spontaneous canine osteosarcoma with F(ab')2 fragments of osteosarcoma-associated monoclonal antibody TP-1
   Anticancer Res, 12 (6B), 2151-7
   PubMed 1295462

Publications 1990

1. Fjeld JG, Bruland OS, Benestad HB, Schjerven L, Stigbrand T, Nustad K (1990)
   Radioimmunotargeting of human tumour cells in immunocompetent animals
   Br J Cancer, 62 (4), 573-8
   DOI 10.1038/bjc.1990.332, PubMed 2223574

Publications 1989

1. Haines DM, Bruland OS (1989)
   Immunohistochemical detection of osteosarcoma-associated antigen in canine osteosarcoma
   Anticancer Res, 9 (4), 903-7
   PubMed 2684000

Publications 1988

1. Bruland OS, Fodstad O, Stenwig AE, Pihl A (1988)
   Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen
   Cancer Res, 48 (18), 5302-9
   PubMed 2457439